<DOC>
	<DOCNO>NCT01482169</DOCNO>
	<brief_summary>The purpose study demonstrate intravenous regadenoson equivalent intravenous Adenoscan® physiological assessment intermediate coronary lesion .</brief_summary>
	<brief_title>Intravenous Regadenoson Versus Intravenous Adenoscan® Fractional Flow Reserve ( FFR )</brief_title>
	<detailed_description>This prospective open label , single center pilot trial evaluate regadenoson compare Adenoscan® give IV assessment Fractional Flow Reserve . Forty eight subject enrol get Adenoscan® administer via IV follow Regadenoson IV .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients undergo elective left heart catheterization Age ≥ 18 year ( female child bear potential ) Able provide write informed consent Contraindications administration either Adenoscan® Regadenoson High degree AV block , sick sinus syndrome without function pacemaker Symptomatic bradycardia Recent STEMI ( &lt; 5 day ) Recent NSTEMI ( &lt; 5 day ) peak CK &gt; 1000 IU Dipyridamole use within 24 hour Adenoscan® contraindicate ( hypersensitivity Adenoscan® , Regadenoson , aminophylline Known severe bronchoconstrictive lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Left heart catheterization</keyword>
	<keyword>Fractional flow reserve</keyword>
	<keyword>Adenoscan®</keyword>
	<keyword>Regadenoson</keyword>
</DOC>